Perspective Therapeutics, Inc. $CATX Shares Acquired by UBS Group AG

UBS Group AG increased its stake in Perspective Therapeutics, Inc. (NYSEAMERICAN:CATX) by 44.5% during the 4th quarter, according to its most recent Form 13F filing with the SEC. The fund owned 926,331 shares of the company’s stock after acquiring an additional 285,188 shares during the period. UBS Group AG owned approximately 1.25% of Perspective Therapeutics worth $2,547,000 as of its most recent SEC filing.

Several other hedge funds have also modified their holdings of the stock. Vanguard Group Inc. boosted its position in shares of Perspective Therapeutics by 5.0% in the third quarter. Vanguard Group Inc. now owns 3,437,865 shares of the company’s stock worth $11,792,000 after acquiring an additional 163,532 shares during the last quarter. Geode Capital Management LLC boosted its position in shares of Perspective Therapeutics by 15.8% in the second quarter. Geode Capital Management LLC now owns 1,382,814 shares of the company’s stock worth $4,758,000 after acquiring an additional 188,887 shares during the last quarter. Bank of America Corp DE boosted its position in shares of Perspective Therapeutics by 139.9% in the third quarter. Bank of America Corp DE now owns 785,823 shares of the company’s stock worth $2,695,000 after acquiring an additional 458,323 shares during the last quarter. JPMorgan Chase & Co. boosted its position in shares of Perspective Therapeutics by 118.4% in the second quarter. JPMorgan Chase & Co. now owns 748,067 shares of the company’s stock worth $2,573,000 after acquiring an additional 405,612 shares during the last quarter. Finally, Patient Square Capital LP acquired a new stake in shares of Perspective Therapeutics in the third quarter worth approximately $1,198,000. 54.66% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Several equities research analysts recently issued reports on CATX shares. BTIG Research reissued a “buy” rating and issued a $14.00 target price on shares of Perspective Therapeutics in a research report on Tuesday, March 17th. Truist Financial set a $12.00 price target on shares of Perspective Therapeutics in a report on Tuesday, March 17th. UBS Group raised their price target on shares of Perspective Therapeutics from $7.00 to $8.00 and gave the company a “buy” rating in a report on Wednesday, March 18th. Royal Bank Of Canada cut their price target on shares of Perspective Therapeutics from $18.00 to $14.00 and set an “outperform” rating on the stock in a report on Tuesday, March 17th. Finally, Wedbush restated an “outperform” rating and issued a $11.00 price target on shares of Perspective Therapeutics in a report on Tuesday, May 5th. One research analyst has rated the stock with a Strong Buy rating and eight have issued a Buy rating to the company. According to data from MarketBeat.com, Perspective Therapeutics presently has an average rating of “Buy” and an average target price of $12.63.

Perspective Therapeutics Stock Performance

NYSEAMERICAN CATX opened at $4.16 on Wednesday. Perspective Therapeutics, Inc. has a one year low of $1.96 and a one year high of $6.16. The company’s 50 day moving average price is $4.21 and its 200 day moving average price is $3.67.

Perspective Therapeutics (NYSEAMERICAN:CATX) last posted its quarterly earnings results on Monday, May 11th. The company reported ($0.25) EPS for the quarter, beating the consensus estimate of ($0.29) by $0.04. The firm had revenue of $0.08 million for the quarter, compared to analyst estimates of $0.16 million. Perspective Therapeutics had a negative net margin of 17,982.69% and a negative return on equity of 42.33%. Equities analysts anticipate that Perspective Therapeutics, Inc. will post -1.14 earnings per share for the current year.

Perspective Therapeutics Profile

Perspective Therapeutics, Inc, together with its subsidiaries, develops precision-targeted alpha therapies (TAT) for oncology that treats cancer patients across multiple tumor types comprising metastatic disease. The company discovers, designs, and develop its initial programs candidates consists of VMT-a-NET, that is currently in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2) expressing tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta-emitting therapy; and VMT01, which is currently in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma.